You can buy or sell FibroGen and other stocks, options, ETFs, and crypto commission-free!
FibroGen, Inc. engages in the discovery, development, and commercialization of therapeutics. It focuses on hypoxia-inducible factor and connective tissue growth factor biology to develop innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Read More The company was founded by Thomas B. Neff on September 29, 1993 and is headquartered in San Francisco, CA.
San Francisco, California
52 Week High
52 Week Low
Seeking AlphaFeb 28
FibroGen, Inc. (FGEN) CEO Thomas Neff on Q4 2018 Results - Earnings Call Transcript
FibroGen, Inc. (NASDAQ:FGEN) Q4 2018 Earnings Conference Call February 27, 2019 5:00 PM ET Company Participants Karen Bergman - VP, IR & Corporate Communications Thomas Neff - Founder, Chairman & CEO Peony Yu - Chief Medical Officer Christine Chung - SVP, China Operations Elias Kouchakji - SVP Clinical Development, Drug Safety & Pharmacovigilance Pat Cotroneo - CFO Conference Call Participants Michael Yee - Jefferies Adam Walsh - Stifel, Nicolaus & Company Geoffrey Porges - SVB Leerink Joel Beat...
Stock Price, News, & Analysis for FibroGen
FibroGen, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical deve...
Markets InsiderFeb 22
FibroGen Reports Fourth Quarter and Full Year 2018 Financial Results
SAN FRANCISCO, Feb. 22, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics, today announced that it will report fourth quarter and full year 2018 financial results on Wednesday, February 27, 2019 after market close, and will host a conference call to discuss financial results and provide a business update at 5:00 p.m. ET (2:00 p.m. PT). Conference Call and Audio Webcast Interested parties may ac...
Expected May 9, After Hours